Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid Services (CMS)

WARREN, N.J.–(BUSINESS WIRE)–Alcresta Therapeutics, Inc. announced the issuance of a permanent and
unique billing code by the Centers for Medicare and Medicaid Services
(CMS) for RELiZORB. RELiZORB is an in-line digestive enzyme cartridge
and is indicated for use in pediatric patients (ages 5 years and above)
and adult patients to hydrolyze fats in enteral formula.

A permanent HCPCS billing code for RELiZORB (B4105, “In-Line Cartridge
Containing Digestive Enzymes(s) for Enteral Feeding, Each”) is effective
January 1, 2019. The Medicare coverage indicator for B4105 is “C”
(Contractor Discretion) and the Medicare pricing indicator is “39”
(Parenteral and Enteral Nutrition), meaning that RELiZORB can now be
covered and separately reimbursed under Medicare rules.

“This reimbursement milestone makes RELiZORB accessible to many patients
that had previously been denied access due to coding issues. In clinical
trials and published reports, RELiZORB has been shown to normalize
absorption of key fatty acids, decrease gastrointestinal adverse events
like diarrhea, and increase weight in patients suffering from fat
malabsorption as a consequence of cystic fibrosis and other serious
diseases. RELiZORB can be an important option for these patients, as
there is no other drug or medical device approved by the FDA to do what
RELiZORB does. RELiZORB is already used by approximately 50% of all
enterally fed cystic fibrosis patients in the U.S.” said Tasos
Konidaris, CFO of Alcresta Therapeutics.

About Alcresta® Therapeutics, Inc.

Alcresta Therapeutics, Inc. is dedicated to developing and
commercializing novel, enzyme-based products designed to address
challenges faced by patients living with gastrointestinal disorders and
rare diseases. The company uses its proprietary technology platform to
support a broad pipeline of products, with an initial focus on
pancreatic insufficiency, which results in malabsorption common in
cystic fibrosis, digestive cancers, premature birth, and other serious
diseases.

The Alcresta Therapeutics, Inc. management team has extensive experience
in pharmaceutical, medical devices, and nutritional product development.
The corporate office is based in Warren, New Jersey with additional RD
sites in the Boston, MA area and is backed by top-tier investors:
Athyrium Capital Management, Bessemer Venture Partners, HealthQuest
Capital, Frazier Healthcare Partners, and Third Rock Ventures. More
information can be found at www.alcresta.com.